PBA
BBIO icon

Paradigm Biocapital Advisors’s BridgeBio Pharma BBIO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-684,277
Closed -$52.3M – 36
2025
Q4 		$52.3M Hold
684,277
– – 1.34% 18
2025
Q3 		$35.5M Sell
684,277
-281,487
-29% -$13.7M 1.01% 25
2025
Q2 		$41.7M Buy
+965,764
New +$35.1M 1.78% 15
2024
Q3 		– Sell
-1,089,492
Closed -$27.6M – 37
2024
Q2 		$27.6M Buy
+1,089,492
New +$29.8M 1.06% 25

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradigm Biocapital Advisors's BBIO Position: Q1 2026 in Review

Paradigm Biocapital Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 684,277 shares — an estimated $52.3M sold.

Paradigm Biocapital Advisors first reported a position in BBIO in Q2 2024 and held it in 4 quarters. The position peaked at $52.3M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Paradigm Biocapital Advisors reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 684,277 BridgeBio Pharma shares in Q1 2026, an estimated $52.3M.
  • Paradigm Biocapital Advisors first reported a position in BridgeBio Pharma in Q2 2024 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's BridgeBio Pharma position peaked at $52.3M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.